A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Nevanimibe (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Sponsors Millendo Therapeutics
- 23 Oct 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.
- 23 Oct 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2020.
- 04 Apr 2017 Trial design presented at The 99th Annual Meeting of the Endocrine Society